Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 15, 2018. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions executed on January 11, 2018.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| January 11, 2018 | Ordinary Shares (25p each) | £13.3087 | 352 shares | London Stock Exchange (XLON) |
Note: The total volume of 352 shares is the aggregate of individual transactions by nine executives.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine share acquisitions resulting from dividend reinvestment under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Transaction Nature: All reported share acquisitions were made via the reinvestment of dividends paid on January 11, 2018, under the Share Reward Plan.
- Participants: Transactions involved nine senior executives, including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and President of R&D (Dr P J T Vallance).
- Share Price: The execution price for all transactions was uniform at £13.3087 per share.
- Scope: This filing does not contain financial performance data; investors should refer to Form 20-F for comprehensive financial results.